- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr James Auran Previews Ophthalmic Trauma–Focused Content at AAO 2021
James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, explains what he is most looking forward to at the 2021 conference of the American Academy of Ophthalmology (AAO).
The field of ophthalmic trauma began to receive more attention around 2 or 3 years ago, explained James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma. Auran will chair a session at the American Academy of Ophthalmology's 2021 conference, taking place November 12-15, on the responsibilities of the on-call ophthalmologist.
Transcript
What are you most looking forward to at the American Academy of Ophthalmology's 2021 conference?
I'm Dr Jim Auran. I'm a professor of ophthalmology at Columbia University and I've had the honor of being president of the American Society of Ophthalmic Trauma for the past 2 years. I think what I'm looking forward to most is that we have some pretty comprehensive instruction courses going, all because of the gracious efforts of the academy to allow us to do so. We have a poster session and a symposium. Trauma has been the poor stepchild of ophthalmology for a long time. There's been a tremendous amount of interest and many people have dedicated their lives to it, but they hadn't got the traction until recently. I guess it just hit a critical point about 2 to 3 years ago and here we are.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
